Experimental Treatments for Lennox Gastaut syndrome

Bexicaserin is an oral therapy being developed by Lundbeck to treat seizures associated with Lennox-Gastaut syndrome (LGS) and other forms of severe pediatric epilepsy. The medication is designed to bind to a receptor that responds to serotonin, a chemical messenger in the brain. This is expected to boost inhibitory signals that can calm the excessive nerve cell activity that causes seizures.

Carisbamate is an investigational oral therapy being developed by SK Biopharmaceuticals for the treatment of seizures in people with Lennox-Gastaut syndrome (LGS). Seizures are caused by excessive, synchronized nerve cell firing. Carisbamate, formulated as an oral liquid, is designed to block certain sodium channels on the surface of nerve cells. By preventing sodium from entering the cells, carisbamate helps control their firing and prevent seizures.

EPX-100 (clemizole hydrochloride) is an experimental oral therapy being developed by Harmony Biosciences for the treatment of Lennox-Gastaut syndrome (LGS). The main ingredient in EPX-100 is clemizole hydrochloride, an antihistamine medication used decades ago for treating allergies. It aims to control seizures in LGS by modulating activity at receptors that respond to the brain signaling chemical serotonin. This is expected to help control the abnormal nerve cell signaling that causes seizures.